{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:09:24Z","timestamp":1780466964118,"version":"3.54.1"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>STUDY QUESTION<\/jats:title>\n                    <jats:p>Does artificial cycle (AC) endometrial preparation result in increased pregnancy loss rates in patients undergoing vitrified-warmed euploid blastocyst transfer (frozen embryo transfer (FET))?<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>SUMMARY ANSWER<\/jats:title>\n                    <jats:p>The randomized controlled trial (RCT) demonstrates that artificial endometrial preparation is associated with significantly higher early pregnancy loss (EPL) compared to natural cycles when transferring euploid embryos.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>WHAT IS KNOWN ALREADY<\/jats:title>\n                    <jats:p>The increased use of FET cycles has fueled discussion regarding the optimal endometrial preparation method. While earlier reviews found no significant differences in pregnancy outcomes between preparation strategies, recent studies suggest that artificial preparation may be associated with higher pregnancy loss rates and, more recently, with hypertensive disorders of pregnancy. However, these findings were not confirmed in a recent RCT using genetically untested embryos. Since up to 70% of EPLs are attributed to genetic anomalies in the embryo, analyzing FET of euploid embryos provides a more accurate evaluation of the impact of endometrial preparation on pregnancy loss.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>STUDY DESIGN, SIZE, DURATION<\/jats:title>\n                    <jats:p>An RCT was conducted in a university hospital (May 2019\u2013May 2024) investigating the impact of endometrial preparation on pregnancy loss in FET. A power calculation based on internal data determined that 261 patients per arm were needed to detect an increase in pregnancy loss from 9.9% in tNC-FET to 18.4% in AC-FET (80% power, 5% significance). Due to safety concerns regarding hypertensive disorders following AC-FET, the trial was discontinued after enrolling 354 patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PARTICIPANTS\/MATERIALS, SETTING, METHODS<\/jats:title>\n                    <jats:p>Women aged 18\u201342\u2009years undergoing FET after preimplantation genetic testing for aneuploidy (PGT-A) with or without testing for a monogenic disorder (PGT-M) or a structural chromosomal rearrangement (PGT-SR) were randomized (1:1) to either true NC-FET (spontaneous ovulation without luteal phase support (LPS)) or AC-FET (using estradiol and single-route LPS). Only the first FET per patient using a euploid blastocyst was included. The primary outcome was EPL (before 8\u2009weeks of gestation). Secondary outcomes included clinical pregnancy rate (CPR), ongoing pregnancy, live birth rate (LBR), and obstetric outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MAIN RESULTS AND THE ROLE OF CHANCE<\/jats:title>\n                    <jats:p>Between May 2019 and May 2024, 354 patients were randomized (NC-FET: 178, AC-FET: 176). In the intention-to-treat analysis, EPL per started FET cycle occurred in 6.7% of patients in the NC-FET group and 14.2% in the AC-FET group (P\u2009=\u20090.022). Additionally, EPL per positive hCG was 9.0% in the NC-FET group and 21.6% in the AC-FET group (P\u2009=\u20090.006). CPRs were significantly higher in the NC-FET group (72.5% versus 52.3%, P\u2009&amp;lt;\u20090.001), as were LBRs (67.4% versus 47.2%, P\u2009&amp;lt;\u20090.001). The study was prematurely terminated after obstetrical safety concerns of AC-FET emerged from other studies. While obstetric and neonatal outcomes did not differ significantly between groups in our study, the trial was not powered for these endpoints. Despite the premature halt, the observed difference in EPL was in line with the anticipated effect size.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>LIMITATIONS, REASONS FOR CAUTION<\/jats:title>\n                    <jats:p>Although this randomized study achieved the estimated difference in the primary outcome, the premature cessation necessitates cautious interpretation. Additionally, the absence of luteal phase progesterone measurements in both groups represents a limitation. Nevertheless, these findings offer valuable insights for counseling patients on the optimal FET preparation method.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>WIDER IMPLICATIONS OF THE FINDINGS<\/jats:title>\n                    <jats:p>The results of this RCT reinforce concerns regarding AC-FET cycles. In addition to previously reported higher obstetrical complications, an increased risk of pregnancy loss was associated with AC-FET cycles. This protocol should therefore preferentially be used in patients with (premature) ovarian insufficiency or those resistant to ovulation induction agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>STUDY FUNDING\/COMPETING INTEREST(S)<\/jats:title>\n                    <jats:p>No external funding was received for this study. C.R. declares speaker\u2019s fees from Organon, Ferring, Abbott, IBSA; travel support from Gedeon Richter, Ferring, Organon, Abbott, IBSA. S.S.-R. declares employment and stock ownership in IVIRMA Lisboa; grants\/contracts (paid to institution) from Theramex, Organon, Gedeon-Richter, Roche Pharmaceuticals; consulting fees from Organon, IBSA, Besins; travel support (paid to institution) and speaker\u2019s fees from Organon, Ferring, Theramex, IBSA, Gedeon-Richter, Abbott, and Besins; being a member of the Executive Committee, Past-Senior Deputy of Safety and Quality SIG for ESHRE. S.M. declares grants\/contracts (to institution) from Merck, Gedeon Richter, Ferring; advisory board for Oxolife; speakers\u2019 fees and travel support from Merck, Gedeon Richter, Ferring, and IBSA. W.V. declares research grants (to institution) from Merck B.V. and IBSA; consulting fees (to institution) from CooperSurgical and Cook Medical; advisory board (payment to institution) for Goodlife; speaker fees (to institution) from CooperSurgical, Merck B.V., Organon Pharma B.V., Ferring B.V., and Gedeon Richter. C.B. declares speaker\u2019s fees from Abbott, Ferring Pharmaceuticals, IBSA, Organon, Gedeon Richter, and Merck. The other authors declare no conflict of interest related to this manuscript.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>TRIAL REGISTRATION NUMBER<\/jats:title>\n                    <jats:p>Clinicaltrials.gov: NCT03976544<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>TRIAL REGISTRATION DATE<\/jats:title>\n                    <jats:p>6 April 2019<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATE OF FIRST PATIENT\u2019S ENROLMENT<\/jats:title>\n                    <jats:p>25 May 2019<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/humrep\/deag060","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T11:50:44Z","timestamp":1775217044000},"page":"910-917","source":"Crossref","is-referenced-by-count":0,"title":["The impact of endometrial preparation on pregnancy loss in vitrified-warmed euploid blastocyst transfer cycles: a randomized controlled trial"],"prefix":"10.1093","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-4632-0717","authenticated-orcid":false,"given":"C","family":"Roelens","sequence":"first","affiliation":[{"name":"Brussels IVF, UZ Brussel , Brussels,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Santos-Ribeiro","sequence":"additional","affiliation":[{"name":"IVI Lisbon, Department of Obstetrics and Gynaecology, Faculty of Medicine, University of Lisbon , Lisbon,","place":["Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Mackens","sequence":"additional","affiliation":[{"name":"Brussels IVF, UZ Brussel , Brussels,","place":["Belgium"]},{"name":"Research Group Genetics Reproduction and Development (GRAD), Vrije Universiteit Brussel , Brussels,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"De Vos","sequence":"additional","affiliation":[{"name":"Brussels IVF, UZ Brussel , Brussels,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Keymolen","sequence":"additional","affiliation":[{"name":"Clinical Sciences, Research Group Genetics, Reproduction and Development, Centre for Medical Genetics, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel) , Brussels,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0243-8650","authenticated-orcid":false,"given":"P","family":"Verdyck","sequence":"additional","affiliation":[{"name":"Clinical Sciences, Research Group Genetics, Reproduction and Development, Centre for Medical Genetics, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel) , Brussels,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5019-5924","authenticated-orcid":false,"given":"M","family":"De Vos","sequence":"additional","affiliation":[{"name":"Brussels IVF, UZ Brussel , Brussels,","place":["Belgium"]},{"name":"Research Group Genetics Reproduction and Development (GRAD), Vrije Universiteit Brussel , Brussels,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9863-9309","authenticated-orcid":false,"given":"H","family":"Tournaye","sequence":"additional","affiliation":[{"name":"Brussels IVF, UZ Brussel , Brussels,","place":["Belgium"]},{"name":"Research Group Genetics Reproduction and Development (GRAD), Vrije Universiteit Brussel , Brussels,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W","family":"Verpoest","sequence":"additional","affiliation":[{"name":"Department of Reproductive Medicine, Utrecht University Medical Centre (UMCU), Utrecht University , Utrecht,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7129-5158","authenticated-orcid":false,"given":"C","family":"Blockeel","sequence":"additional","affiliation":[{"name":"Brussels IVF, UZ Brussel , Brussels,","place":["Belgium"]},{"name":"Research Group Genetics Reproduction and Development (GRAD), Vrije Universiteit Brussel , Brussels,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"key":"2026060301515117400_deag060-B1","doi-asserted-by":"crossref","first-page":"103774","DOI":"10.1016\/j.rbmo.2023.103774","article-title":"Modified natural cycle allows a window of 7 days for frozen embryo transfer planning","volume":"49","author":"Alonso-Mayo","year":"2024","journal-title":"Reprod Biomed Online"},{"key":"2026060301515117400_deag060-B2","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1093\/humrep\/deq125","article-title":"Circulating progesterone levels and ongoing pregnancy rates in controlled ovarian stimulation cycles for in vitro fertilization: analysis of over 4000 cycles","volume":"25","author":"Bosch","year":"2010","journal-title":"Hum Reprod"},{"key":"2026060301515117400_deag060-B3","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1093\/humrep\/det048","article-title":"Blastocyst biopsy and vitrification are effective for preimplantation genetic diagnosis of monogenic diseases","volume":"28","author":"Chang","year":"2013","journal-title":"Hum Reprod"},{"key":"2026060301515117400_deag060-B4","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s10815-024-03041-9","article-title":"Pathologic maternal and neonatal outcomes associated with programmed embryo transfer","volume":"41","author":"Conrad","year":"2024","journal-title":"J Assist Reprod Genet"},{"key":"2026060301515117400_deag060-B5","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3390\/genes16020134","article-title":"Trophectoderm biopsy: present state of the art","volume":"16","author":"De Vos","year":"2025","journal-title":"Genes (Basel)"},{"key":"2026060301515117400_deag060-B6","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1093\/humrep\/der251","article-title":"An OHSS-free clinic by segmentation of IVF treatment","volume":"26","author":"Devroey","year":"2011","journal-title":"Hum Reprod"},{"key":"2026060301515117400_deag060-B7","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1038\/s41591-023-02645-5","article-title":"Prevalence of chromosomal alterations in first-trimester spontaneous pregnancy loss","volume":"29","author":"Essers","year":"2023","journal-title":"Nat Med"},{"key":"2026060301515117400_deag060-B8","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1093\/humrep\/dead197","article-title":"ART in Europe, 2019: results generated from European registries by ESHRE","volume":"38","author":"European IVF Monitoring Consortium (EIM) for the European Society of Human Reproduction and Embryology (ESHRE)","year":"2023","journal-title":"Hum Reprod"},{"key":"2026060301515117400_deag060-B9","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1093\/humrep\/deaa092","article-title":"Low progesterone levels on the day before natural cycle frozen embryo transfer are negatively associated with live birth rates","volume":"35","author":"Gaggiotti-Marre","year":"2020","journal-title":"Hum Reprod"},{"key":"2026060301515117400_deag060-B10","first-page":"CD003414","article-title":"Cycle regimens for endometrial preparation prior to frozen embryo transfer","volume":"6","author":"Ghobara","year":"2025","journal-title":"Cochrane Database Syst Rev"},{"key":"2026060301515117400_deag060-B11","first-page":"CD002118","article-title":"Cleavage-stage versus blastocyst-stage embryo transfer in assisted reproductive technology","volume":"5","author":"Glujovsky","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"2026060301515117400_deag060-B12","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0140-6736(24)00756-6","article-title":"Livebirth rate after one frozen embryo transfer in ovulatory women starting with natural, modified natural, or artificial endometrial preparation in Viet Nam: an open-label randomised controlled trial","volume":"404","author":"Ho","year":"2024","journal-title":"Lancet"},{"key":"2026060301515117400_deag060-B13","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1093\/humrep\/deaa322","article-title":"Impact of low serum progesterone levels on the day of embryo transfer on pregnancy outcome: a prospective cohort study in artificial cycles with vaginal progesterone","volume":"36","author":"Labarta","year":"2021","journal-title":"Hum Reprod"},{"key":"2026060301515117400_deag060-B14","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.fertnstert.2019.09.003","article-title":"Effect of endometrial thickness on ectopic pregnancy in frozen embryo transfer cycles: an analysis including 17,244 pregnancy cycles","volume":"113","author":"Liu","year":"2020","journal-title":"Fertil Steril"},{"key":"2026060301515117400_deag060-B15","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1093\/humrep\/dex285","article-title":"Frozen embryo transfer: a review on the optimal endometrial preparation and timing","volume":"32","author":"Mackens","year":"2017","journal-title":"Hum Reprod"},{"key":"2026060301515117400_deag060-B16","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.rbmo.2023.02.007","article-title":"Individualized luteal phase support using additional oral dydrogesterone in artificially prepared frozen embryo transfer cycles: is it beneficial?","volume":"46","author":"Mackens","year":"2023","journal-title":"Reprod Biomed Online"},{"key":"2026060301515117400_deag060-B17","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1016\/j.fertnstert.2021.07.002","article-title":"Serum luteal phase progesterone in women undergoing frozen embryo transfer in assisted conception: a systematic review and meta-analysis","volume":"116","author":"Melo","year":"2021","journal-title":"Fertil Steril"},{"key":"2026060301515117400_deag060-B18","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1093\/humrep\/deae061","article-title":"Natural proliferative phase frozen embryo transfer-a new approach which may facilitate scheduling without hindering pregnancy outcomes","volume":"39","author":"Mendes Godinho","year":"2024","journal-title":"Hum Reprod"},{"key":"2026060301515117400_deag060-B19","first-page":"139","article-title":"Oocyte, embryo and blastocyst cryopreservation in ART: systematic review and meta-analysis comparing slow-freezing versus vitrification to produce evidence for the development of global guidance","volume":"23","author":"Rienzi","year":"2017","journal-title":"Hum Reprod Update"},{"key":"2026060301515117400_deag060-B20","doi-asserted-by":"crossref","first-page":"104789","DOI":"10.1016\/j.rbmo.2024.104789","article-title":"Cycle management in frozen embryo transfer: the best of all worlds?","volume":"50","author":"Roelens","year":"2025","journal-title":"Reprod Biomed Online"},{"key":"2026060301515117400_deag060-B21","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1093\/humrep\/dev218","article-title":"A prospective randomized controlled trial investigating the effect of artificial shrinkage (collapse) on the implantation potential of vitrified blastocysts","volume":"30","author":"Van Landuyt","year":"2015","journal-title":"Hum Reprod"},{"key":"2026060301515117400_deag060-B22","doi-asserted-by":"crossref","first-page":"hoac007","DOI":"10.1093\/hropen\/hoac007","article-title":"Impact of endometrial preparation on early pregnancy loss and live birth rate after frozen embryo transfer: a large multicenter cohort study (14 421 frozen cycles)","volume":"2022","author":"Vinsonneau","year":"2022","journal-title":"Hum Reprod Open"},{"key":"2026060301515117400_deag060-B23","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1161\/HYPERTENSIONAHA.118.12043","article-title":"Increased preeclampsia risk and reduced aortic compliance with in vitro fertilization cycles in the absence of a corpus luteum","volume":"73","author":"von Versen-H\u00f6ynck","year":"2019","journal-title":"Hypertension"},{"key":"2026060301515117400_deag060-B24","doi-asserted-by":"crossref","first-page":"104954","DOI":"10.1016\/j.rbmo.2025.104954","article-title":"Search for optimal frozen embryo transfer endometrial preparation protocol continues despite a large randomized trial\u2019s findings","volume":"51","author":"Yarali","year":"2025","journal-title":"Reprod Biomed Online"},{"key":"2026060301515117400_deag060-B25","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1093\/humupd\/dmad011","article-title":"Obstetric and neonatal outcomes after natural versus artificial cycle frozen embryo transfer and the role of luteal phase support: a systematic review and meta-analysis","volume":"29","author":"Zaat","year":"2023","journal-title":"Hum Reprod Update"},{"key":"2026060301515117400_deag060-B26","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1093\/humrep\/dex234","article-title":"The international glossary on infertility and fertility care, 2017","volume":"32","author":"Zegers-Hochschild","year":"2017","journal-title":"Hum Reprod"}],"container-title":["Human Reproduction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/humrep\/advance-article-pdf\/doi\/10.1093\/humrep\/deag060\/68209331\/deag060.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/humrep\/advance-article-pdf\/doi\/10.1093\/humrep\/deag060\/68209331\/deag060.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T05:52:00Z","timestamp":1780465920000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/humrep\/article\/41\/6\/910\/8667126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":26,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,5,4]]},"published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/humrep\/deag060","relation":{},"ISSN":["0268-1161","1460-2350"],"issn-type":[{"value":"0268-1161","type":"print"},{"value":"1460-2350","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,5,4]]}}}